230 related articles for article (PubMed ID: 27131756)
21. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
[TBL] [Abstract][Full Text] [Related]
23. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.
Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F
Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma.
Siva S; Pham D; Gill S; Corcoran NM; Foroudi F
BJU Int; 2012 Dec; 110(11 Pt B):E737-43. PubMed ID: 23107102
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
[TBL] [Abstract][Full Text] [Related]
27. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S
J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849
[TBL] [Abstract][Full Text] [Related]
30. Commentary on "A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma." Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia.: BJU Int 2012;110(11 Pt B):E737-43. doi: 10.1111/j.1464-410X.2012.11550.x. [Epub 2012 Oct 29].
Gottschalk A
Urol Oncol; 2014 Apr; 32(3):374-5. PubMed ID: 24679465
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.
Kothari G; Foroudi F; Gill S; Corcoran NM; Siva S
Acta Oncol; 2015 Feb; 54(2):148-57. PubMed ID: 25140860
[TBL] [Abstract][Full Text] [Related]
32. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
33. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
34. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.
Ponsky L; Lo SS; Zhang Y; Schluchter M; Liu Y; Patel R; Abouassaly R; Welford S; Gulani V; Haaga JR; Machtay M; Ellis RJ
Radiother Oncol; 2015 Oct; 117(1):183-7. PubMed ID: 26362723
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.
Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
37. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
38. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
